Abstract:Background Advanced glycation end-products (AGEs) are elevated under diabetic conditions and associated with insulin resistance, endothelial dysfunction and vascular inflammation in humans. It has been demonstrated that AGEs evoke oxidative and inflammatory reactions in endothelial cells through the interaction with a receptor for AGEs (RAGE). Here, we aimed to identify the cellular mechanisms by which AGEs exacerbate the endothelial dysfunction in human coronary artery endothelial cells (HCAECs). Methods 30 type 2 diabetic patients with or without coronary artery atherosclerosis were recruited for this study. Plasma levels of AGE peptides (AGE-p) were analyzed using flow injection assay. Endothelial function was tested by brachial artery flow-mediated vasodilatation (FMD). Further investigations were performed to determine the effects and mechanisms of AGEs on endothelial dysfunction in HCAECs. Results AGE-p was inversely associated with FMD in diabetic patients with coronary artery atherosclerosis in our study. After treated with AGEs, HCAECs showed significant reductions of eNOS mRNA and protein levels including eNOS and phospho-eNOS Ser1177, eNOS mRNA stability, eNOS enzyme activity, and cellular nitric oxide (NO) levels, whereas superoxide anion production was significantly increased. In addition, AGEs significantly decreased mitochondrial membrane potential, ATP content and catalase and superoxyde dismutase (SOD) activities, whereas it increased NADPH oxidase activity. Treatment of the cells with antioxidants SeMet, SOD mimetic MnTBAP and mitochondrial inhibitor thenoyltrifluoroacetone (TTFA) effectively blocked these effects induced by AGEs. AGEs also increased phosphorylation of the mitogen-activated protein kinases p38 and ERK1/2, whereas the specific inhibitors of p38, ERK1/2, and TTFA effectively blocked AGEs-induced reactive oxygen species production and eNOS downregulation. Conclusions AGEs cause endothelial dysfunction by a mechanism associated with decreased eNOS expression and increased oxidative stress in HCAECs through activation of p38 and ERK1/2.

AGEs Decreased SIRT3 Expression and SIRT3 Activation Protected AGEs-Induced EPCs’ Dysfunction and Strengthened Anti-oxidant Capacity

High Glucose And Free Fatty Acids Induce Endothelial Progenitor Cell Senescence Via Pgc-1 Alpha/Sirt1 Signaling Pathway

Erk And Akt Signaling Pathways Are Involved In Advanced Glycation End Product-Induced Autophagy In Rat Vascular Smooth Muscle Cells

Rosiglitazone Via Upregulation of Akt/Enos Pathways Attenuates Dysfunction of Endothelial Progenitor Cells, Induced by Advanced Glycation End Products

Rosiglitazone ameliorates the dysfunction of endothelial progenitor cells induced by advanced glycation end products

The Role of RAGE, MAPK and NF-κB Pathway in the Advanced Glycation End-Products Induced HUVECs Dysfunction

Advanced glycation endproducts alter functions and promote apoptosis in endothelial progenitor cells through receptor for advanced glycation endproducts mediate overpression of cell oxidant stress

SIRT3 protects endothelial cells from high glucose-induced senescence and dysfunction via the p53 pathway

Sirt3 Overexpression Alleviates Hyperglycemia-Induced Vascular Inflammation Through Regulating Redox Balance, Cell Survival, and AMPK-mediated Mitochondrial Homeostasis

Advanced glycation end products depress function of endothelial progenitor cells via p38 and ERK 1/2 mitogen-activated protein kinase pathways

Advanced Glycation End Products Alters Functions of End Othelial Progenitor Cells in Vitro

GW24-e2135 SIRT1 Significantly Influences Old Sourced MSCs Aging and Proliferation

SIRT3 attenuates coronary atherosclerosis in diabetic patients by regulating endothelial cell function

Advanced glycation end-products decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells

Accelerated onset of senescence of endothelial progenitor cells in patients with type 2 diabetes mellitus: role of dimethylarginine dimethylaminohydrolase 2 and asymmetric dimethylarginine.

Sirt1 Resists Advanced Glycation End Products-Induced Expressions of Fibronectin and TGF-β1 by Activating the Nrf2/ARE Pathway in Glomerular Mesangial Cells.

Inhibition of Mitochondrial Oxidative Damage Improves Reendothelialization Capacity of Endothelial Progenitor Cells Via SIRT3 (sirtuin 3)-Enhanced SOD2 (superoxide Dismutase 2) Deacetylation in Hypertension.

Advanced Glycation End Products Impair Function of Late Endothelial Progenitor Cells Through Effects on Protein Kinase Akt and Cyclooxygenase-2

Emerging role of SIRT3 in endothelial metabolism, angiogenesis, and cardiovascular disease

AGEs/RAGE Promote Osteogenic Differentiation in Rat Bone Marrow-Derived Endothelial Progenitor Cells via MAPK Signaling

Polydatin Promotes Nrf2-ARE Anti-Oxidative Pathway Through Activating Sirt1 to Resist AGEs-induced Upregulation of Fibronetin and Transforming Growth Factor-Β1 in Rat Glomerular Messangial Cells.